Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma

Christopher M. Russell, Kathy Lue, John Fisher, Wassim Kassouf, Thomas Schwaab, Wade J. Sexton, Simon Tanguay, Sarah P. Psutka, Robert Houston Thompson, Bradley C. Leibovich, Michael I. Hanzly, Philippe E. Spiess, Stephen A. Boorjian

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To evaluate the outcome of patients after surgical resection of isolated retroperitoneal lymph node (RPLN) recurrence of renal cell carcinoma (RCC) using a multicentre international cohort. Patients and Methods: In all, 50 patients were identified who underwent resection of isolated RPLN recurrence of RCC at four institutions after nephrectomy for pT<inf>any</inf>N<inf>any</inf>M0 disease. Progression-free (PFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to assess the association of clinicopathological characteristics with disease progression. Results: The median (interquartile range, IQR) age at resection was 57.0 (50.0-62.5) years. The median (IQR) time to RPLN recurrence after nephrectomy was 12.6 (6.9-39.5) months, with no significant difference in median time to RPLN recurrence between patients with N+ disease at nephrectomy (10.7 [6.5-24.6] months) and those with Nx/pN0 disease at nephrectomy (13.7 [8.7-44.2] months) (P = 0.66). The median (IQR) size of the RPLN recurrence before resection was 2.6 (1.9-5) cm. The most common site for RPLN recurrence was within the interaortocaval region (34%). The median (IQR) follow-up after RPLN resection for patients alive at last follow-up was 28.0 (13.7-51.2) months. During follow-up, 26 patients developed RCC recurrence, at a median (IQR) of 9.9 (4.0-18.5) months after RPLN resection. Of those who developed a secondary recurrence, disease was again isolated to the retroperitoneum in seven patients. In all, 11 patients subsequently died, including 10 who died from disease. The median PFS after RPLN resection was 19.5 months, with a 3- and 5-year PFS of 40.5% and 35.4%, respectively. We also found that RPLN recurrence at ≤12 months after nephrectomy was associated with a significantly inferior median PFS (12.3 months) compared with RPLN recurrence at >12 months after nephrectomy (47.6 months; P = 0.003). Moreover, on multivariate analysis, a shorter time to recurrence remained associated with a significantly increased risk for subsequent disease progression (hazard ratio 3.51; P = 0.005). Conclusion: Surgical resection of isolated RPLN recurrence from RCC may result in durable cancer control in appropriately selected patients. Recurrence at ≤12 months after nephrectomy was associated with a significantly increased risk of progression after resection, underscoring the importance of this variable for risk stratification. Thus, we recommend that, in the setting of isolated RPLN recurrence of RCC (in patients without precluding comorbidities), careful consideration with the patients and medical oncology colleagues be undertaken about the relative and individualised benefits of surgical resection, systemic therapy, and surveillance.

Original languageEnglish (US)
JournalBJU International
DOIs
StateAccepted/In press - 2015

Fingerprint

Renal Cell Carcinoma
Lymph Nodes
Recurrence
Nephrectomy
Disease Progression
Medical Oncology
Proportional Hazards Models
Comorbidity
Neoplasms
Multivariate Analysis

Keywords

  • Isolated nodal recurrence
  • Kidney cancer
  • Lymph node
  • Renal cell carcinoma
  • Retroperitoneal

ASJC Scopus subject areas

  • Urology

Cite this

Russell, C. M., Lue, K., Fisher, J., Kassouf, W., Schwaab, T., Sexton, W. J., ... Boorjian, S. A. (Accepted/In press). Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. BJU International. https://doi.org/10.1111/bju.13212

Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. / Russell, Christopher M.; Lue, Kathy; Fisher, John; Kassouf, Wassim; Schwaab, Thomas; Sexton, Wade J.; Tanguay, Simon; Psutka, Sarah P.; Thompson, Robert Houston; Leibovich, Bradley C.; Hanzly, Michael I.; Spiess, Philippe E.; Boorjian, Stephen A.

In: BJU International, 2015.

Research output: Contribution to journalArticle

Russell, CM, Lue, K, Fisher, J, Kassouf, W, Schwaab, T, Sexton, WJ, Tanguay, S, Psutka, SP, Thompson, RH, Leibovich, BC, Hanzly, MI, Spiess, PE & Boorjian, SA 2015, 'Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma', BJU International. https://doi.org/10.1111/bju.13212
Russell, Christopher M. ; Lue, Kathy ; Fisher, John ; Kassouf, Wassim ; Schwaab, Thomas ; Sexton, Wade J. ; Tanguay, Simon ; Psutka, Sarah P. ; Thompson, Robert Houston ; Leibovich, Bradley C. ; Hanzly, Michael I. ; Spiess, Philippe E. ; Boorjian, Stephen A. / Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. In: BJU International. 2015.
@article{05183b1721d6474ebad1a73c230ef607,
title = "Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma",
abstract = "Objective: To evaluate the outcome of patients after surgical resection of isolated retroperitoneal lymph node (RPLN) recurrence of renal cell carcinoma (RCC) using a multicentre international cohort. Patients and Methods: In all, 50 patients were identified who underwent resection of isolated RPLN recurrence of RCC at four institutions after nephrectomy for pTanyNanyM0 disease. Progression-free (PFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to assess the association of clinicopathological characteristics with disease progression. Results: The median (interquartile range, IQR) age at resection was 57.0 (50.0-62.5) years. The median (IQR) time to RPLN recurrence after nephrectomy was 12.6 (6.9-39.5) months, with no significant difference in median time to RPLN recurrence between patients with N+ disease at nephrectomy (10.7 [6.5-24.6] months) and those with Nx/pN0 disease at nephrectomy (13.7 [8.7-44.2] months) (P = 0.66). The median (IQR) size of the RPLN recurrence before resection was 2.6 (1.9-5) cm. The most common site for RPLN recurrence was within the interaortocaval region (34{\%}). The median (IQR) follow-up after RPLN resection for patients alive at last follow-up was 28.0 (13.7-51.2) months. During follow-up, 26 patients developed RCC recurrence, at a median (IQR) of 9.9 (4.0-18.5) months after RPLN resection. Of those who developed a secondary recurrence, disease was again isolated to the retroperitoneum in seven patients. In all, 11 patients subsequently died, including 10 who died from disease. The median PFS after RPLN resection was 19.5 months, with a 3- and 5-year PFS of 40.5{\%} and 35.4{\%}, respectively. We also found that RPLN recurrence at ≤12 months after nephrectomy was associated with a significantly inferior median PFS (12.3 months) compared with RPLN recurrence at >12 months after nephrectomy (47.6 months; P = 0.003). Moreover, on multivariate analysis, a shorter time to recurrence remained associated with a significantly increased risk for subsequent disease progression (hazard ratio 3.51; P = 0.005). Conclusion: Surgical resection of isolated RPLN recurrence from RCC may result in durable cancer control in appropriately selected patients. Recurrence at ≤12 months after nephrectomy was associated with a significantly increased risk of progression after resection, underscoring the importance of this variable for risk stratification. Thus, we recommend that, in the setting of isolated RPLN recurrence of RCC (in patients without precluding comorbidities), careful consideration with the patients and medical oncology colleagues be undertaken about the relative and individualised benefits of surgical resection, systemic therapy, and surveillance.",
keywords = "Isolated nodal recurrence, Kidney cancer, Lymph node, Renal cell carcinoma, Retroperitoneal",
author = "Russell, {Christopher M.} and Kathy Lue and John Fisher and Wassim Kassouf and Thomas Schwaab and Sexton, {Wade J.} and Simon Tanguay and Psutka, {Sarah P.} and Thompson, {Robert Houston} and Leibovich, {Bradley C.} and Hanzly, {Michael I.} and Spiess, {Philippe E.} and Boorjian, {Stephen A.}",
year = "2015",
doi = "10.1111/bju.13212",
language = "English (US)",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma

AU - Russell, Christopher M.

AU - Lue, Kathy

AU - Fisher, John

AU - Kassouf, Wassim

AU - Schwaab, Thomas

AU - Sexton, Wade J.

AU - Tanguay, Simon

AU - Psutka, Sarah P.

AU - Thompson, Robert Houston

AU - Leibovich, Bradley C.

AU - Hanzly, Michael I.

AU - Spiess, Philippe E.

AU - Boorjian, Stephen A.

PY - 2015

Y1 - 2015

N2 - Objective: To evaluate the outcome of patients after surgical resection of isolated retroperitoneal lymph node (RPLN) recurrence of renal cell carcinoma (RCC) using a multicentre international cohort. Patients and Methods: In all, 50 patients were identified who underwent resection of isolated RPLN recurrence of RCC at four institutions after nephrectomy for pTanyNanyM0 disease. Progression-free (PFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to assess the association of clinicopathological characteristics with disease progression. Results: The median (interquartile range, IQR) age at resection was 57.0 (50.0-62.5) years. The median (IQR) time to RPLN recurrence after nephrectomy was 12.6 (6.9-39.5) months, with no significant difference in median time to RPLN recurrence between patients with N+ disease at nephrectomy (10.7 [6.5-24.6] months) and those with Nx/pN0 disease at nephrectomy (13.7 [8.7-44.2] months) (P = 0.66). The median (IQR) size of the RPLN recurrence before resection was 2.6 (1.9-5) cm. The most common site for RPLN recurrence was within the interaortocaval region (34%). The median (IQR) follow-up after RPLN resection for patients alive at last follow-up was 28.0 (13.7-51.2) months. During follow-up, 26 patients developed RCC recurrence, at a median (IQR) of 9.9 (4.0-18.5) months after RPLN resection. Of those who developed a secondary recurrence, disease was again isolated to the retroperitoneum in seven patients. In all, 11 patients subsequently died, including 10 who died from disease. The median PFS after RPLN resection was 19.5 months, with a 3- and 5-year PFS of 40.5% and 35.4%, respectively. We also found that RPLN recurrence at ≤12 months after nephrectomy was associated with a significantly inferior median PFS (12.3 months) compared with RPLN recurrence at >12 months after nephrectomy (47.6 months; P = 0.003). Moreover, on multivariate analysis, a shorter time to recurrence remained associated with a significantly increased risk for subsequent disease progression (hazard ratio 3.51; P = 0.005). Conclusion: Surgical resection of isolated RPLN recurrence from RCC may result in durable cancer control in appropriately selected patients. Recurrence at ≤12 months after nephrectomy was associated with a significantly increased risk of progression after resection, underscoring the importance of this variable for risk stratification. Thus, we recommend that, in the setting of isolated RPLN recurrence of RCC (in patients without precluding comorbidities), careful consideration with the patients and medical oncology colleagues be undertaken about the relative and individualised benefits of surgical resection, systemic therapy, and surveillance.

AB - Objective: To evaluate the outcome of patients after surgical resection of isolated retroperitoneal lymph node (RPLN) recurrence of renal cell carcinoma (RCC) using a multicentre international cohort. Patients and Methods: In all, 50 patients were identified who underwent resection of isolated RPLN recurrence of RCC at four institutions after nephrectomy for pTanyNanyM0 disease. Progression-free (PFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to assess the association of clinicopathological characteristics with disease progression. Results: The median (interquartile range, IQR) age at resection was 57.0 (50.0-62.5) years. The median (IQR) time to RPLN recurrence after nephrectomy was 12.6 (6.9-39.5) months, with no significant difference in median time to RPLN recurrence between patients with N+ disease at nephrectomy (10.7 [6.5-24.6] months) and those with Nx/pN0 disease at nephrectomy (13.7 [8.7-44.2] months) (P = 0.66). The median (IQR) size of the RPLN recurrence before resection was 2.6 (1.9-5) cm. The most common site for RPLN recurrence was within the interaortocaval region (34%). The median (IQR) follow-up after RPLN resection for patients alive at last follow-up was 28.0 (13.7-51.2) months. During follow-up, 26 patients developed RCC recurrence, at a median (IQR) of 9.9 (4.0-18.5) months after RPLN resection. Of those who developed a secondary recurrence, disease was again isolated to the retroperitoneum in seven patients. In all, 11 patients subsequently died, including 10 who died from disease. The median PFS after RPLN resection was 19.5 months, with a 3- and 5-year PFS of 40.5% and 35.4%, respectively. We also found that RPLN recurrence at ≤12 months after nephrectomy was associated with a significantly inferior median PFS (12.3 months) compared with RPLN recurrence at >12 months after nephrectomy (47.6 months; P = 0.003). Moreover, on multivariate analysis, a shorter time to recurrence remained associated with a significantly increased risk for subsequent disease progression (hazard ratio 3.51; P = 0.005). Conclusion: Surgical resection of isolated RPLN recurrence from RCC may result in durable cancer control in appropriately selected patients. Recurrence at ≤12 months after nephrectomy was associated with a significantly increased risk of progression after resection, underscoring the importance of this variable for risk stratification. Thus, we recommend that, in the setting of isolated RPLN recurrence of RCC (in patients without precluding comorbidities), careful consideration with the patients and medical oncology colleagues be undertaken about the relative and individualised benefits of surgical resection, systemic therapy, and surveillance.

KW - Isolated nodal recurrence

KW - Kidney cancer

KW - Lymph node

KW - Renal cell carcinoma

KW - Retroperitoneal

UR - http://www.scopus.com/inward/record.url?scp=84937149286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937149286&partnerID=8YFLogxK

U2 - 10.1111/bju.13212

DO - 10.1111/bju.13212

M3 - Article

C2 - 26118331

AN - SCOPUS:84937149286

JO - BJU International

JF - BJU International

SN - 1464-4096

ER -